Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cabergoline-associated erythema nodosum.

Prashant Kaushik1, Matt R Soule, Wesley A Ellison

  • 1School of Medicine & Health Sciences, University of North Dakota, Bismarck, ND, USA. kaushikprashant@gmail.com

The Annals of Pharmacotherapy
|January 4, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPR120/free fatty acid receptor 4 (FFAR-4) agonists, antagonists, allosteric modulators: Computational drug design and discovery review.

European journal of medicinal chemistry·2026
Same author

Advanced theoretical engineering of KM<sub>3</sub>H<sub>9</sub> (M = Fe, Co, Ni, Cu) hydrides for novel applications in hydrogen storage.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Investigating the spatial adaptation for iron and zinc content using AMMI and GGE biplot model in lentil (Lens culinaris L.).

BMC plant biology·2026
Same author

Responsible Innovation in AI-Driven Teledentistry: Ethical, Legal, and Economic Considerations for the Globalization Era.

Discoveries (Craiova, Romania)·2026
Same author

Over 600 million people aged 18-65 will have headache tomorrow: global 1-day prevalence and recall bias from a meta-analysis of individual participant data (N = 38,512) from the general populations of 15 countries.

The journal of headache and pain·2026
Same author

A Novel <i>De Novo</i> Assembly Approach for Transcriptome Profiling and Marker Identification in <i>Grewia Asiatica</i> (Phalsa), a Medicinal Plant, Across Leaf And Root Tissues.

Current genomics·2026
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Cabergoline therapy for microprolactinoma may cause erythema nodosum (panniculitis) and joint inflammation. These adverse effects were reversible upon drug withdrawal, suggesting a probable causal link.

Area of Science:

  • Endocrinology
  • Dermatology
  • Rheumatology

Background:

  • Cabergoline is a dopamine agonist used to treat hyperprolactinemia, often caused by pituitary microprolactinomas.
  • Adverse effects of cabergoline can include pleuropulmonary and cardiac issues, but skin manifestations are less commonly reported.

Observation:

  • A patient on cabergoline for microprolactinoma developed erythema nodosum (EN) with associated inflammatory arthropathy.
  • Histological confirmation of EN and resolution of symptoms after cabergoline cessation supported the diagnosis.
  • A lower-dose rechallenge with cabergoline resulted in milder EN recurrence, further indicating drug association.

Findings:

  • Cabergoline was likely associated with the development of erythema nodosum (panniculitis) and inflammatory arthritis.

Related Experiment Videos

  • The Naranjo probability scale indicated a probable adverse drug event.

    • Implications:

    • Erythema nodosum and panniculitis should be considered potential, reversible adverse effects of cabergoline treatment for microprolactinoma.
    • Clinicians should monitor for dermatological and rheumatological symptoms in patients receiving cabergoline.